PERK and eIF2α activation are increasingly recognised in postmortem analyses of patients with neurodegenerative disorders, including Alzheimer’s disease, the tauopathies and prion disorders. Here, EIF2A is linked to early-onset autosomal dominant Alzheimer disease.